My journey after a mild infection with COVID-19: I want my old brain back

ABSTRACT

Although neurocognitive dysfunction has been observed after infection by SARS-CoV-2, few studies have detailed these alterations or demonstrated their impact on daily life activities and work. Here, I describe the sequence of events following a mild COVID-19 infection in August 2020 (which now is described as “post-COVID syndrome”) and comment on my ensuing limitations associated with cognitive difficulties, headache, fatigue and sleepiness. Furthermore, I discuss the efforts that I have made to recover from my infection since its beginning and the strategies adopted for living with persistent restrictions in terms of cognitive performance.

RESUMO

Embora a disfunção neurocognitiva tenha sido observada após a infecção por SARS-Cov2, poucos estudos detalharam essas alterações ou demonstraram seu impacto nas atividades de vida diária e trabalho. Aqui eu descrevo a sequência de eventos após uma infecção leve por COVID-19 em agosto de 2020 (agora considerada Síndrome pós-COVID) e comento as limitações associadas às dificuldades cognitivas, dor de cabeça, fadiga e sonolência. Além disso, eu caracterizo o esforço de recuperação desde o início e as estratégias para conviver com restrições persistentes em termos de desempenho cognitivo.

Keywords:

COVID-19 - Cognitive Dysfunction - Post-COVID Syndrome - Fatigue

Palavras-chave:

COVID-19 - Disfunção Cognitiva - Síndrome Pós-COVID - Fadiga

Publication History

Received: 13 March 2022

Accepted: 14 March 2022

Article published online:
06 February 2023

• REFERENCES

• 1 Alwan NA, Attree E, Blair JM, Bogaert D, Bowen MA, Boyle J. et al. From doctors as patients: a manifesto for tackling persisting symptoms of covid-19. BMJ 2020; 370: m3565 https://doi.org/10.1136/bmj.m3565
• 2 Ritchie K, Chan D, Watermeyer T. The cognitive consequences of the COVID-19 epidemic: collateral damage?. Brain Commun 2020; 2 (02) fcaa069 https://doi.org/10.1093/braincomms/fcaa069
• 3 Yen P-H, Kuan Y-C, Tam K-W, Chung C-C, Hong C-T, Huang Y-H. Efficacy of levetiracetam for migraine prophylaxis: a systematic review and meta-analysis. J Formos Med Assoc 2021; 120 (01) 03 755-764 https://doi.org/10.1016/j.jfma.2020.08.020
• 4 Wandschneider B, Stretton J, Sidhu M, Centeno M, Kozák LR, Symms M. et al. Levetiracetam reduces abnormal network activations in temporal lobe epilepsy. Neurology 2014; 83 (17) 1508-1512 https://doi.org/10.1212/WNL.20220062202200620910
• 5 Guadagni V, Drogos LL, Tyndall AV, Davenport MH, Anderson TJ, Eskes GA. et al. Aerobic exercise improves cognition and cerebrovascular regulation in older adults. Neurology 2020; 94 (21) e2245-57 https://doi.org/10.1212/WNL.20220062202200629478
• 6 Nalbandian A, Sehgal K, Gupta A, Madhavan MV, McGroder C, Stevens JS. et al. Post-acute COVID-19 syndrome. Nat Med 2021; 27 (04) 601-615 https://doi.org/10.1038/s41591-021-01283-z
• 7 Crunfli F, Carregari VC, Veras FP, Vendramini PH, Valença AGF, Antunes ASLM. et al. Morphological, cellular and molecular basis of brain infection in COVID-19 patients. MedRxiv [Preprint]. 2022 2020.2010.2009.20207464 https://doi.org/10.1101/2020.10.09.20207464
• 8 Douaud G, Lee S, Alfaro-Almagro F, Arthofer C, Wang C, McCarthy P. et al. SARS-CoV-2 is associated with changes in brain structure in UK Biobank. Nature 2022; 604 7907 697-707 https://doi.org/10.1038/s41586-022-04569-5
• 9 Taquet M, Holmes EA, Harrison PJ. Depression and anxiety disorders during the COVID-19 pandemic: knowns and unknowns. Lancet 2021; 398 10312 1665-1666 https://doi.org/10.1016/S0140-6736(21)02221-2
• 10 COVID-19 Mental Disorders Collaborators. Global prevalence and burden of depressive and anxiety disorders in 204 countries and territories in 2020 due to the COVID-19 pandemic. Lancet 2021; 398 10312 1700-1712 https://doi.org/10.1016/S0140-6736(21)02143-7